It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GMED’s FA Score shows that 0 FA rating(s) are green whileRSLS’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GMED’s TA Score shows that 4 TA indicator(s) are bullish while RSLS’s TA Score has 5 bullish TA indicator(s).
GMED (@Medical/Nursing Services) experienced а +11.00% price change this week, while RSLS (@Medical/Nursing Services) price change was +45.19% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +7.60%. For the same industry, the average monthly price growth was +7.99%, and the average quarterly price growth was +7.38%.
GMED is expected to report earnings on Nov 11, 2025.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
GMED | RSLS | GMED / RSLS | |
Capitalization | 8.11B | 37.4M | 21,674% |
EBITDA | 553M | -6.28M | -8,810% |
Gain YTD | -27.433 | -96.484 | 28% |
P/E Ratio | 23.26 | 0.01 | 192,007% |
Revenue | 2.51B | 7.18M | 34,997% |
Total Cash | 461M | 2.52M | 18,330% |
Total Debt | 92.3M | 130K | 71,000% |
GMED | RSLS | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 18 | 34 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 74 Overvalued | 52 Fair valued | |
PROFIT vs RISK RATING 1..100 | 76 | 100 | |
SMR RATING 1..100 | 84 | 99 | |
PRICE GROWTH RATING 1..100 | 56 | 65 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RSLS's Valuation (52) in the Medical Specialties industry is in the same range as GMED (74). This means that RSLS’s stock grew similarly to GMED’s over the last 12 months.
GMED's Profit vs Risk Rating (76) in the Medical Specialties industry is in the same range as RSLS (100). This means that GMED’s stock grew similarly to RSLS’s over the last 12 months.
GMED's SMR Rating (84) in the Medical Specialties industry is in the same range as RSLS (99). This means that GMED’s stock grew similarly to RSLS’s over the last 12 months.
GMED's Price Growth Rating (56) in the Medical Specialties industry is in the same range as RSLS (65). This means that GMED’s stock grew similarly to RSLS’s over the last 12 months.
GMED's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as RSLS (100). This means that GMED’s stock grew similarly to RSLS’s over the last 12 months.
GMED | RSLS | |
---|---|---|
RSI ODDS (%) | 2 days ago63% | 2 days ago90% |
Stochastic ODDS (%) | 2 days ago62% | 2 days ago83% |
Momentum ODDS (%) | 2 days ago70% | 2 days ago89% |
MACD ODDS (%) | 2 days ago72% | 2 days ago90% |
TrendWeek ODDS (%) | 2 days ago65% | 2 days ago83% |
TrendMonth ODDS (%) | 2 days ago64% | 2 days ago80% |
Advances ODDS (%) | 3 days ago65% | 2 days ago87% |
Declines ODDS (%) | 16 days ago58% | 5 days ago90% |
BollingerBands ODDS (%) | 2 days ago57% | 2 days ago90% |
Aroon ODDS (%) | 2 days ago61% | N/A |
A.I.dvisor indicates that over the last year, GMED has been loosely correlated with CVRX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GMED jumps, then CVRX could also see price increases.
Ticker / NAME | Correlation To GMED | 1D Price Change % | ||
---|---|---|---|---|
GMED | 100% | -4.41% | ||
CVRX - GMED | 46% Loosely correlated | -6.22% | ||
CTKB - GMED | 46% Loosely correlated | -2.16% | ||
VREX - GMED | 44% Loosely correlated | +0.84% | ||
ILMN - GMED | 42% Loosely correlated | -1.01% | ||
A - GMED | 42% Loosely correlated | -1.18% | ||
More |
A.I.dvisor indicates that over the last year, RSLS has been loosely correlated with BIAF. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if RSLS jumps, then BIAF could also see price increases.
Ticker / NAME | Correlation To RSLS | 1D Price Change % | ||
---|---|---|---|---|
RSLS | 100% | +22.50% | ||
BIAF - RSLS | 46% Loosely correlated | -8.86% | ||
HSCS - RSLS | 35% Loosely correlated | -0.28% | ||
GMED - RSLS | 31% Poorly correlated | -4.41% | ||
AZTA - RSLS | 30% Poorly correlated | -4.64% | ||
LFWD - RSLS | 29% Poorly correlated | -14.64% | ||
More |